Emodin / Catalase Cancer Research Results

EMD, Emodin: Click to Expand ⟱

Features:

Organic compound isolated from rhubarb, buckthorn, knotweed. It has laxative, anticancer, antibacterial, antiinflammatory, and antiviral activities, and is used in traditional Chinese medicine.
Emodin, an anthraquinone derivative found in various plants (e.g., rhubarb, Polygonum cuspidatum).

Pathways:
- Generation of Reactive Oxygen Species (ROS)
- Upregulation Bax downregulation of Bcl‑2, caspase activation and cyt_c release.
- Induce cell cycle arrest at various checkpoints (commonly G0/G1 or G2/M phases.
- Can inhibit NF‑κB activation
– MAPK Pathways
– PI3K/Akt Pathway
- Metalloproteinases (MMPs)

-ic50 cancer cells 10-50uM, normal cells higher(supports a therapeutic window)

Rhubarb species	Common name	Plant part analyzed	Emodin content	Aloe-emodin content	Interpretation
Rheum palmatum	Chinese rhubarb	Dried root and rhizome	Approximately 1.1–2.0 mg/g	Approximately 0.65–1.0 mg/g	Major medicinal source; concentrations vary considerably with origin, plant age, processing, and extraction method.
Rheum officinale	Medicinal rhubarb	Dried root and rhizome	Usually approximately 0.5–2 mg/g	Usually approximately 0.5–2 mg/g	Composition broadly resembles R. palmatum; some samples contain more aloe-emodin than emodin.
Rheum tanguticum	Tangut rhubarb	Root and rhizome; smaller amounts occur in aerial tissues	Moderate to high; commonly approximately 1–3 mg/g in underground tissues	Moderate; commonly below emodin	One of the three principal Chinese medicinal rhubarb species. Tissue distribution differs, and some aerial tissues may contain appreciable emodin.
Rheum australe syn. Rheum emodi	Himalayan or Indian rhubarb	Root and rhizome	Present and frequently a major anthraquinone	Present, generally lower and more variable	Reported concentrations vary widely among wild populations; quantitative results are not directly comparable across extraction methods.
Rheum rhabarbarum / Rheum × hybridum	Garden or culinary rhubarb	Root and rhizome; edible petiole contains much less	Low to moderate in roots; usually trace or low in petioles	Low or trace in petioles; variable in roots	Edible stalks are not compositionally equivalent to medicinal rhubarb roots. Most anthraquinones occur in underground tissues.

In rhubarb, the medicinal material described as “root and rhizome” includes both the true roots and the thick underground stem base from which the leaf stalks emerge.

Emodin — Emodin is a naturally occurring hydroxyanthraquinone and plant secondary metabolite, chemically identified as 1,3,8-trihydroxy-6-methylanthraquinone. It is a small-molecule natural product rather than an approved anticancer drug. Major sources include rhubarb species, Japanese knotweed, buckthorn, Polygonum multiflorum, Polygonum cuspidatum, Rheum palmatum, and several fungi. Emodin is pharmacologically pleiotropic, with redox-active, kinase-modulating, anti-inflammatory, cytotoxic, laxative, and antimicrobial properties. Its anticancer effects remain predominantly preclinical, and emodin should be distinguished from the related compounds aloe-emodin and rhein.

Primary mechanisms (ranked):

Induction of oxidative stress and mitochondrial dysfunction, producing ROS accumulation, mitochondrial membrane depolarization, cytochrome-c release, and caspase-dependent apoptosis.
Suppression of PI3K/AKT/mTOR and related survival signaling, frequently accompanied by AMPK activation, reduced protein synthesis, metabolic stress, and apoptosis.
Modulation of BAX/BCL-2-family proteins and activation of intrinsic and, in some models, extrinsic apoptotic pathways.
Cell-cycle arrest through context-dependent modulation of p53, p21, ATM, cyclins, CDKs, and checkpoint proteins.
Inhibition of NF-κB, STAT3, TLR4, JAK, MAPK, HER2, CK2, and other pro-survival or inflammatory signaling pathways.
Suppression of glycolysis and anabolic metabolism through reduced GLUT1, HK2, PKM2, LDHA, FASN, and AKT/mTOR activity in selected cancer models.
Inhibition of invasion, epithelial–mesenchymal transition, angiogenesis, and cancer-stem-cell phenotypes through reduced MMPs, HIF-1α, VEGF, TGF-β, CXCR4, and mesenchymal signaling.
Induction of autophagy, ER stress, DNA-damage responses, or necroptosis in model-dependent settings.
NRF2/HO-1 activation as a secondary, context-dependent antioxidant response that may protect normal cells but can also oppose emodin-induced cytotoxic oxidative stress.
Chemosensitization through inhibition of survival, resistance, stemness, cholesterol-metabolism, or drug-efflux pathways; the interaction is drug- and tumor-dependent.

Bioavailability / PK relevance: Native emodin has very poor oral bioavailability, estimated at approximately 3% in rat studies. It has low aqueous solubility, incomplete intestinal absorption, extensive intestinal and hepatic glucuronidation and sulfation, and rapid systemic clearance. Circulating exposure is therefore dominated by conjugated metabolites rather than sustained concentrations of free emodin. Nanoparticles, liposomes, phospholipid complexes, prodrugs, and other delivery systems are being investigated but are not established clinical formulations.

In-vitro vs systemic exposure relevance: Most anticancer experiments use approximately 10–100 µM emodin, commonly 20–50 µM. These free-drug concentrations are unlikely to be maintained systemically after conventional oral administration because of poor absorption and rapid conjugation. In-vitro findings therefore substantially overstate the exposure achievable with unformulated oral emodin. Local gastrointestinal exposure may be higher, but this does not establish therapeutically useful tumor exposure.

Clinical evidence status: Preclinical. Evidence consists primarily of cancer-cell studies and rodent xenograft or chemically induced tumor models. Emodin has shown experimental adjunct and chemosensitizing effects with agents including paclitaxel, sorafenib, cisplatin, gemcitabine, and other therapies, but there is no established randomized clinical evidence supporting emodin as a cancer treatment. Emodin is not an FDA-, EMA-, or Health Canada-approved anticancer agent.

Safety: Emodin is not necessarily tumor-selective and can produce ROS, mitochondrial injury, apoptosis, and genotoxic signals in nonmalignant cells at sufficient concentrations. Preclinical literature reports possible hepatotoxicity, nephrotoxicity, reproductive toxicity, gastrointestinal irritation, laxative effects, and complex mutagenicity findings, particularly with high doses or prolonged exposure. It may also affect CYP enzymes, conjugating enzymes, transporters, and the pharmacokinetics of co-administered drugs. Long-term concentrated supplementation should not be considered equivalent to ordinary dietary exposure from rhubarb or other foods.

Mechanistic Profile of Emodin

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	ROS-driven mitochondrial injury	↑ ROS ↓ mitochondrial membrane potential ↓ ATP	↑ ROS and mitochondrial injury at cytotoxic exposure	P–R	Upstream cytotoxic stress	A central mechanism in many cancer models, but not intrinsically cancer-specific. Redox outcome varies with dose, cell type, antioxidant capacity, and exposure duration.
2	Intrinsic mitochondrial apoptosis	↑ BAX ↓ BCL-2 and BCL-XL ↑ cytochrome-c ↑ caspase-9 and caspase-3 ↑ PARP cleavage	↑ apoptosis at high concentration or prolonged exposure	R–G	Programmed cell death	Frequently follows ROS accumulation and mitochondrial depolarization. Extrinsic Fas and caspase-8 signaling also contributes in some models.
3	PI3K AKT mTOR and AMPK signaling	↓ PI3K ↓ AKT ↓ mTOR ↑ AMPK (context-dependent)	Mixed or tissue-protective modulation (context-dependent)	R–G	Reduced survival and anabolic signaling	Mechanistically important across several tumor types, although AMPK activation is not universal and may differ by metabolic state.
4	Cell-cycle checkpoints and DNA-damage response	↑ ATM ↑ p53 ↑ p21 ↓ cyclin D1, cyclin E, or cyclin B1 ↓ CDK activity	Cell-cycle disturbance possible at cytotoxic exposure	G	G0/G1, S-phase, or G2/M arrest	The arrest point is cell-line and dose-dependent. Emodin should not be assigned to one universal checkpoint.
5	NF-κB TLR4 inflammatory survival signaling	↓ TLR4 ↓ IKK activation ↓ IκBα degradation ↓ NF-κB nuclear activity	↓ inflammatory signaling in many injury models	R–G	Reduced survival, inflammation, and treatment resistance	This axis contributes to both anticancer and anti-inflammatory effects and may reduce cytokine-driven tumor support.
6	JAK STAT3 and receptor kinase signaling	↓ JAK1 and JAK2 ↓ STAT3 ↓ HER2 ↓ CK2 or Src signaling (model-dependent)	Mixed; possible inhibition of physiological kinase signaling	R–G	Reduced proliferation and anti-apoptotic transcription	Direct and indirect kinase effects have been reported, but target dominance varies substantially among tumor models.
7	Glycolysis and metabolic dependency	↓ GLUT1 ↓ HK2 ↓ PKM2 ↓ LDHA ↓ ECAR ↓ glycolysis	PKM2 and metabolic modulation reported (context-dependent)	R–G	Energy stress and reduced biosynthetic capacity	Prominent in selected renal and hepatic cancer models but not yet established as a universal primary mechanism.
8	HIF-1α VEGF angiogenic program	↓ HIF-1α biosynthesis ↓ VEGF ↓ angiogenesis	Potential impairment of physiological hypoxic adaptation at sufficient exposure	G	Reduced hypoxia tolerance and vascular support	Evidence includes reduced HIF-1α protein synthesis rather than exclusively altered transcription or degradation.
9	EMT invasion and extracellular-matrix remodeling	↑ E-cadherin ↓ N-cadherin ↓ vimentin ↓ MMP2 and MMP9 ↓ TGF-β signaling	Possible modulation of wound repair and fibrosis pathways	G	Reduced migration, invasion, and metastatic phenotype	Effects may involve tumor cells, macrophages, stromal signaling, and cancer-stem-cell maintenance.
10	Cancer stemness and differentiation state	↓ CD133 ↓ OCT4 ↓ NOTCH1 ↓ stem-cell formation	Effects on normal progenitor populations are insufficiently characterized	G	Reduced tumor initiation and recurrence-associated phenotype	Supported primarily by cell and animal models; clinically meaningful selectivity has not been established.
11	Autophagy ER stress and necroptosis	↑ autophagy ↑ ER stress or ↓ ER stress (model-dependent) ↑ RIP1 and MLKL signaling in selected models	Protective or toxic depending on tissue and exposure	R–G	Alternative stress-response and death pathways	Autophagy can facilitate death or survival. Necroptosis has been demonstrated in selected renal cancer models but should not be generalized.
12	NRF2 HO-1 antioxidant response	↑ NRF2 ↑ HO-1 (secondary; context-dependent)	↑ NRF2-mediated antioxidant and cytoprotective signaling	R–G	Compensatory antioxidant response	NRF2 activation may limit oxidative injury in normal tissues but could also reduce emodin cytotoxicity or support resistant cancer cells. It is not consistently the primary anticancer mechanism.
13	HDAC and chromatin regulation	↓ HDAC activity ↑ histone acetylation	Epigenetic modulation possible	R–G	Altered transcriptional state	Biochemical HDAC inhibition is reported, but the free concentrations required and its contribution in vivo remain uncertain.
14	Chemosensitization	↑ chemotherapy sensitivity ↓ survival and resistance pathways	Potential ↑ normal-tissue toxicity or altered drug disposition	G	Enhanced response to selected anticancer agents	Reported combinations are promising preclinically, but interactions cannot be assumed beneficial because emodin also affects metabolism, transport, redox balance, and normal-cell viability.
15	Clinical Translation Constraint	↓ free systemic exposure ↑ conjugated metabolites heterogeneous tumor response	Dose-limiting gastrointestinal and organ toxicity concerns	G	Limited translation of in-vitro activity	Approximately 3% oral bioavailability in rat studies, extensive glucuronidation and sulfation, poor solubility, short exposure, absence of validated clinical dosing, and lack of randomized oncology trials are major limitations.

P: 0–30 min R: 30 min–3 hr G: >3 hr

Catalase, Catalase: Click to Expand ⟱

Source:

Type:

Caspases are a cysteine protease that speed up a chemical reaction via pointing their target substrates following an aspartic acid residue.1 They are grouped into apoptotic (caspase-2, 3, 6, 7, 8, 9 and 10) and inflammatory (caspase-1, 4, 5, 11 and 12) mediated caspases.
Caspase-1 may have both tumorigenic or antitumorigenic effects on cancer development and progression, but it depends on the type of inflammasome, methodology, and cancer.
Catalase is an enzyme found in nearly all living cells exposed to oxygen. Its primary role is to protect cells from oxidative damage by catalyzing the conversion of hydrogen peroxide (H₂O₂), a potentially damaging byproduct of metabolism, into water (H₂O) and oxygen (O₂). This detoxification process is crucial because excess H₂O₂ can lead to the formation of reactive oxygen species (ROS) that damage proteins, lipids, and DNA.

Catalase and Cancer
Oxidative Stress and Cancer:
Cancer cells often experience increased levels of oxidative stress due to rapid proliferation and metabolic changes. This stress can lead to DNA damage, promoting tumorigenesis.
Catalase helps mitigate oxidative stress, and its expression can influence the survival and proliferation of cancer cells.
Expression Levels in Different Cancers:
Overexpression: In some cancers, such as breast cancer and certain types of leukemia, catalase may be overexpressed. This overexpression can help cancer cells survive in oxidative environments, potentially leading to more aggressive tumor behavior.
Downregulation: Conversely, in other cancers, such as colorectal cancer, reduced catalase expression has been observed. This downregulation can lead to increased oxidative stress, contributing to tumor progression and metastasis.
Prognostic Implications:
Survival Rates: Studies have shown that high levels of catalase expression can be associated with poor prognosis in certain cancers, as it may enable cancer cells to resist apoptosis (programmed cell death) induced by oxidative stress.

Some types of cancer cells have been reported to exhibit lower catalase activity, possibly increasing their vulnerability to oxidative damage under certain conditions. This vulnerability has even been exploited in some therapeutic strategies (for example, approaches that generate excess H₂O₂ or other ROS specifically targeting cancer cells have been researched).

Scientific Papers found: Click to Expand⟱

6828-

EMD,

Neuroprotective effect of emodin against Alzheimer's disease via Nrf2 signaling in U251 cells and APP/PS1 mice

in-vitro,

AD,

U251

*MMP↑, *ROS↓, *NRF2↑, *HO-1↑, *SOD↑, *Bcl-2↑, *Catalase↑, *BAX↓, *memory↑, *ANXi↓, *Aβ↓, *antiOx↑, *MDA↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Total Targets: 0

Pathway results for Effect on Normal Cells:

Functional Outcomes(tgid=23) ⓘ

ANXi↓, 1, memory↑, 1,
Total Targets: 13

Scientific Paper Hit Count for: Catalase, Catalase

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:75  Target#:46  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

Emodin / Catalase Cancer Research Results

Mechanistic Profile of Emodin

Pathway results for Effect on Cancer / Diseased Cells:

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress(tgid=1) ⓘ

Mitochondria & Bioenergetics(tgid=3) ⓘ

Cell Death(tgid=5) ⓘ

Protein Aggregation(tgid=19) ⓘ

Functional Outcomes(tgid=23) ⓘ

Home Page